Get the Stockscreener App
1.20
0.41%
-0.005
Biocardia Inc stock is traded at $1.20, with a volume of 44,905.
It is down -0.41% in the last 24 hours and down -3.23% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$1.205
Open:
$1.2
24h Volume:
44,905
Relative Volume:
0.58
Market Cap:
$12.74M
Revenue:
$3,000
Net Income/Loss:
$-8.54M
P/E Ratio:
-0.6956
EPS:
-1.7252
Net Cash Flow:
$-7.51M
1W Performance:
-2.44%
1M Performance:
-3.23%
6M Performance:
-14.89%
1Y Performance:
-54.37%
1-Day Range:
$1.15
$1.2599
1-Week Range:
$1.1201
$1.28
52-Week Range:
$1.00
$3.20
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA vs PSNYW, SHMD, GOODO, DWLD, QQQE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
5.30 | 490.27M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
7.42 | 412.57M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
19.92 | 372.90M | 0 | 0 | 0 | 0.00 |
DWLD
Davis Select Worldwide ETF
|
43.93 | 0 | 0 | 0 | 0 | 0.00 |
QQQE
Direxion NASDAQ-100 Equal Weigh
|
99.50 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
BioCardia (BCDA) Projected to Post Quarterly Earnings on Wednesday - Defense World
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit - MSN
BioCardia, Inc. Reports 2026 Financial Results and CardiAMP Clinical Program Updates - Minichart
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ... By GuruFocus - Investing.com Canada
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial Challenges - GuruFocus
BioCardia (BCDA) Highlights Clinical Progress and Financials in Q4 2025 - GuruFocus
BioCardia, Inc.: Advancing Cell Therapy Systems for Heart Failure and Cardiovascular Disease – Clinical Trials, FDA Approvals, and Business Strategies (2025) - Minichart
BioCardia, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:BCDA) 2026-03-24 - Seeking Alpha
Biocardia Inc's HF2 Trial Enrollment and Regulatory Timeline Claims Clash in 2025 Earnings Calls - Bitget
BCDA: Phase III CardiAMP HF data support regulatory filings as financials remain stable and catalysts approach - TradingView
Earnings call transcript: Biocardia’s Q4 2025 results show focus on clinical progress - Investing.com Canada
BioCardia Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BCDA: CardiAMP therapy advances toward regulatory approval with strong clinical data and stable finances - TradingView
BIOCARDIA ($BCDA) Releases Q4 2025 Earnings - Quiver Quantitative
BCDA: Positive clinical trial results and regulatory progress, but net loss widened to $8.2 million - TradingView
[10-K] BioCardia, Inc. Files Annua... - Stock Titan
BioCardia Reports 2025 Business Highlights and Financial Results - marketscreener.com
BioCardia Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
BioCardia, Inc. to Host Conference Call for 2025 Financial Results and Corporate Update on March 24, 2026 - Quiver Quantitative
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026 - GlobeNewswire
BioCardia to give corporate update with 2025 results on March 24 - Stock Titan
Quarterly Risk: Does BioCardia Inc stock have upside surprise potential2026 Technical Overview & Expert Approved Trade Ideas - baoquankhu1.vn
FDA accepts BioCardia pre-submission for Helix catheter By Investing.com - Investing.com South Africa
BioCardia Inc Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA - marketscreener.com
BioCardia Announces FDA Review of Helix Transendocardial Delivery Catheter Pre-Submission Package – Key 2026 Regulatory Milestones - Minichart
FDA accepts BioCardia pre-submission for Helix catheter - Investing.com
BioCardia (BCDA) Advances Heart Catheter Approval with FDA Submi - GuruFocus
BioCardia Advances Helix Catheter Toward FDA Marketing Clearance - TipRanks
BioCardia Announces Pre-Submission Approval Package For Helix Transendocardial Delivery Catheter Accepted By FDA - TradingView
BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA - The Manila Times
BioCardia® Announces FDA Acceptance of Pre-Submission Package for Helix Transendocardial Delivery Catheter - Quiver Quantitative
FDA accepts BioCardia (NASDAQ: BCDA) Helix catheter pre-submission for review - Stock Titan
BioCardia Announces Pre-Submission Approval Package for - GlobeNewswire
Chart Watch: Is now the right time to enter BioCardia IncDay Trade & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
BCDA Stock Price, Quote & Chart | BIOCARDIA INC (NASDAQ:BCDA) - ChartMill
Aug Reactions: Can BioCardia Inc ride the EV wave2026 Performance Recap & Real-Time Stock Entry Alerts - baoquankhu1.vn
Weekly Recap: Is BioCardia Inc a momentum stock2026 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
BioCardia files prospectus for resale of 549K shares; stock down 8.6% - MSN
Market Outlook: Whats the profit margin of BioCardia IncJuly 2025 EndofMonth & Weekly Top Stock Performers List - baoquankhu1.vn
Clinical Trial: ECG Outcomes Have Reduced Negative Remodeling of Heart Volumes - Diagnostic and Interventional Cardiology
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT) - Bitget
BioCardia Highlights Positive CardiAMP Phase III Heart Failure Data - TipRanks
BioCardia reports positive echocardiography results from Phase III CardiAMP HF trial indicating reduced ventricular remodeling - TradingView
New CardiAMP HF echo data from BioCardia (NASDAQ: BCDA) highlight ventricular remodeling - Stock Titan
Heart failure cell therapy shows less adverse cardiac remodeling - Stock Titan
BCDA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BCDA Should I Buy - Intellectia AI
Loss Report: Can BioCardia Inc ride the EV wavePortfolio Profit Report & Daily Growth Stock Tips - baoquankhu1.vn
BioCardia (NASDAQ:BCDA) Trading Up 3.1% – Here’s Why - Defense World
Chipmakers Recap: Does BioCardia Inc have pricing powerQuarterly Performance Summary & Fast Gaining Stock Reports - baoquankhu1.vn
S P Trends: Can BioCardia Inc. ride the EV waveMarket Trend Review & Verified Short-Term Plans - mfd.ru
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):